紫杉醇脂质体相关性溶血性尿毒症性综合征1例附文献复习

目的：紫杉醇是新一代化疗药物,已经被用于非小细胞肺癌的一线治疗。其主要副反应是过敏性休克,而溶血性尿毒症性综合征（HUS）很少见诸报道。我们诊治了1例经过紫杉醇脂质体和顺铂联合化疗后出现HUS的患者,并获得成功。方法：一位54岁女性肺癌术后患者,紫杉醇脂质体和顺铂联合化疗后出现一系列临床症状、体征并经实验室检查。结果：诊断明确后经过血浆置换等治疗,患者痊愈出院。结论：紫杉醇脂质体相关性溶血性尿毒症性综合征是一种临床少见的并发症,临床医生对于该病应该保持高度的警惕,及时鉴别诊断和正确治疗。

Hemolyticuremic syndrome associated with paclitaxellipsome：A case report and review of literature

Objective：Paclitaxel is a new antitumor drug which has been used in first line chemotherapy of non - small cell lung cancer（NSCLC）. The major side effect is hypersensitive reaction, but hemolytic -uremic syndrome （HUS） is rare . We present a case of HUS that developed during the first cycle of combination chemotherapy with paclitaxel - lipsome and cisplantin. Methods： A 54 - year - old female was administered chemotherapy with paclitaxel - lipsome and cisplantin for a stage Ⅲ a NSCLC. At the beginning of the first cycle chemotherapy, the patient developed clinical and laboratory abnormalities consistent with the development of the HUS. Results： Chemotherapy was discontinued, the patient was managed with plasma exchange and so on. Finally the patient recovered completely. Conclusion：The HUS is a rare complication of paclitaxel - based chemotherapy. Clinicians need to maintain a high index of suspicion to diagnose and treat this life - threatening adverse event.